SCHEMBL3944357

SCHEMBL3944357

CCP(=O)(O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTRN P46939 10/20 0.71
CASP3 P42574 4/20 0.57
SENP7 Q9BQF6 3/20 0.57
SENP6 Q9GZR1 2/20 0.57
SENP8 Q96LD8 1/20 0.57
HTR2B P41595 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
MAOA P21397 1/20 0.53
ADRA1A P35348 1/20 0.53
MAPT P10636 2/20 0.52
NPC1 O15118 1/20 0.51
POLB P06746 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2245505 0.83 UTRN (1.00) UTRNHTR2B
SCHEMBL15899770 0.76 UTRN (0.62) UTRNCASP3SENP7SENP6SENP8
SCHEMBL2242304 0.75 CASP3 (0.69) UTRNCASP3SENP7SENP6SENP8
SCHEMBL11310904 0.75 NPC1 (0.74) UTRNCASP3SENP7SENP6SENP8
SCHEMBL2243999 0.73 UTRN (0.70) UTRNCASP3SENP7SENP6SENP8
SCHEMBL2089505 0.73 SMN1; SMN2 (0.63) UTRNCASP3SENP7SENP6SENP8
SCHEMBL10218249 0.73 SMN1; SMN2 (0.82) UTRNCASP3SENP7SENP6SENP8
SCHEMBL2246261 0.73 MAPT (0.67) CASP3SENP7SENP6SENP8SMN1; SMN2
SCHEMBL2242854 0.72 MAPT (0.67) CASP3SENP7SENP6SENP8MAOA
SCHEMBL5052834 0.72 CASP3 (0.59) CASP3SENP7SENP6SENP8SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009021750-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-19 WO disclosed